IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析*

doi:10.3969/j.issn.1672-5069.2019.06.013

摘要/Abstract

摘要： 目的探讨检测血干扰素λ4（IFNL4）和白介素-28B（IL-28B）基因多态性对慢性乙型肝炎（CHB）患者抗病毒治疗后应答的评估价值。方法 2015年3月~2017年3月收治的CHB患者140例,均接受聚乙二醇干扰素α-2a治疗12个月。应用市售试剂盒检测外周血IFNL4和IL-28B基因多态性。结果在治疗结束时,在140例CHB患者中,108例（77.1%）获得应答,32例（22.9%）无应答;应答组IL-28Brsrs8099917位点基因TT型占比为88.9%,显著高于无应答组的68.8%（P<0.05）;应答组血清ALT、AST和HBV DNA水平分别为（35.4±3.2） U/L、（38.6±2.1） U/L和（3.8±2.1） lg copies/ml,均显著低于无应答组的（61.5±4.8） U/L、（73.5±3.0） U/L和（5.2±3.1）lg copies/ml（P<0.05）;125例IFNL4 TT/TT型患者血清ALT、AST和HBV DNA水平分别为（47.1±2.5） U/L、（49.1±1.6） U/L和（4.5±1.2） lg copies/ml,与15例TT/△G型患者的（48.0±2.1） U/L、（59.4±1.5） U/L和（4.7±1.3）lg copies/ml比,无显著性差异（P>0.05）;118例IL-28B TT型患者血清ALT、AST和HBV DNA水平分别为（36.4±2.1） U/L、（38.9±2.7） U/L和（4.0±1.7） lg copies/ml,显著低于22例TG型患者【分别为（59.0±1.4） U/L、（72.1±1.1） U/L和（6.0±2.1） lg copies/ml（P<0.05）。结论 CHB患者IFNL4rs368234815位点基因以TT/TT型和IL-28Brs8099917位点基因以TT型居多,检测IFNL4基因多态性可能对预测抗病毒疗效无明显指导意义,而检测IL-28B基因多态性可能对抗病毒疗效有一定的预测价值。

关键词: 慢性乙型肝炎, 聚乙二醇干扰素α-2a;, 干扰素λ4;, 白介素-28B, 应答, 预测

Abstract: Objective The aim of this study was to explore the prediction of response to peginterferon alfa-2a by blood interferon lambda 4（IFNL4） and interleukin-28B（IL-28B） gene polymorphisms in patients with chronic hepatitis B（CHB）. Methods 140 patients with CHB were enrolled in our hospital between March 2015 and March 2017,and all the patients were given peginterferon alfa-2a for antiviral therapy for 12 months. The blood genetic polymorphisms of IFNL4 and IL-28B were assayed by PCR. Results At the end of discontinuation of the regimen,108 patients （77.1%） responded,and 32 （22.9%） didn’ t responded to the anti-viral therapy;the percentage of IL-28Brsrs8099917 type TT was 88.9%,significantly higher than 68.8% （P<0.05） in non-responders;serum ALT,AST and HBV DNA levels in responders were（35.4±3.2） U/L,（38.6±2.1） U/L and （3.8±2.1） lg copies/ml,significantly lower than （61.5±4.8） U/L,（73.5±3.0） U/L and （5.2±3.1） lg copies/ml （P<0.05） in non-responders;serum ALT,AST and HBV DNA levels in 125 patients with IFNL4 type TT/TT were（47.1±2.5）U/L, （49.1±1.6） U/L and （4.5±1.2） lg copies/ml,not significantly different as compared to （48.0±2.1） U/L,（59.4±1.5）U/L and （4.7±1.3） lg copies/ml in 15 patients with type TT/△G （P>0.05）;serum ALT,AST and HBV DNA levels in 118 patients with IL-28B type TT were（36.4±2.1） U/L,（38.9±2.7） U/L and（4.0±1.7） lg copies/ml,significantly lower than [（59.0±1.4） U/L,（72.1±1.1） U/L and （6.0±2.1） lg copies/ml,respectively,P<0.05] in 22 patients with type TG. Conclusion The majority of CHB patients have genotype TT/TT of IFNL4rs368234815 and genotype TT of IL-28Brs8099917,and the detection of IL-28B gene polymorphism might,and that of IFNL4 polymorphism might not predict the response to anti-viral therapy in patients with CHB,which needs further investigation.

Key words: Chronic hepatitis B, Peginterferon alfa-2a, Interferon lambda 4, Interleukin-28B, Response, Prediction

张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.

patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in[J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.

参考文献

[1] 侯春艳,杨永峰. 慢性乙型肝炎抗病毒治疗新进展. 实用肝脏病杂志,2017,20(1):124-128.
[2] 赵文莉,贺新祥,胡勤明. 恩替卡韦初始单药与拉米夫定和阿德福韦酯初始联合治疗HBeAg阳性慢性乙型肝炎的疗效及安全性. 现代中西医结合杂志,2017,26(5):535-537.
[3] Bersoffmatcha S J,Cao K,Jason M,et al.Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis c virus:A review of cases reported to the U.S. food and drug administration adverse event reporting system. Ann Intern Med, 2017,166(11):792-798.
[4] Eslam M,Mcleod D,Kelaeng K S,et al.IFN-λ3,not IFN-λ4,likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet,2017,49(5):795-800.
[5] Murakawa M,Asahina Y,Kawai-Kitahata F,et al.Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. J Med Virol,2017,89(7):1241-1247.
[6] Ma N,Zhang X,Yang L,et al.Role of functional IFNL4,IFNLR1,IFNA,IFNAR2 polymorphisms in hepatitis B virus-related liver disease in Han Chinese population. J Viral Hepat,2018,25(3):306-313.
[7] Zhu D Y,Deng X Z,Zhu Y M,et al.Association of IL-28B,TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. Arch Virol,2018,163(5):1-10.
[8] Corrales I,Solano C,Amat P,et al.IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. J Med Virol,2017,89(4):685-695.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[10] Thabet K,Chan H L Y,Petta S,et al. The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology,2017,65(6):1840-1850.
[11] Kim G A,Lim Y S,Han S,et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut,2017,67(5):945-952.
[12] Wong R J,Nguyen M T,Trinh H N,et al.Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients:A community-based real-world study. J Viral Hepat,2017,24(12):1089-1097.
[13] Mak L Y,Wong K H,Cheung K S,et al.Hepatitis B core-related antigen (HBcrAg):an emerging marker for chronic hepatitis B virus infection. Aliment Pharm Ther,2018,47(1):43-54.
[14] Alter H,Block T M,Brown N,et al.A research agenda for curing chronic hepatitis B virus infection. Hepatology,2018,67(3):1127-1131.
[15] O'Brien T R,Pfeiffer R M,Paquin A,et al. Comparison of functional variants in IFNL4 and IFNL3 for association with hepatitis C virus clearance. J Hepatol,2015,63(5):1103-1110.
[16] Limothai U,Wasitthankasem R,Poovorawan Y,et al.Single nucleotide polymorphism of interferon lambda-4 gene is not associated with treatment response to pegylated interferon in thai patients with chronic hepatitis B. Asian Pac J Cancer Prev,2015,16(13):5515-5519.
[17] Xie X,Zhang L,Chen Y Z.Association between IFNL4 rs36-8234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy:A meta-analysis. Hum Immunol,2016,77(7):609-615.
[18] Attallah A M,Omran D,Marie M S,et al. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Brit J Biomed Sci,2018,75(4)157-162.
[19] Biswas A,Firdaus R,Gupta D,et al.Interferon λ3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. Transfusion,2017,57(6):1376-1384.
[20] Naeemi H,Aslam R,Raza S M,et al.Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol,2018,163(4):1-12.

IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*

Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[10]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[11]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[14]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[15]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.